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a  b  s  t  r  a  c  t
Aims:  To  assess  if  individuals  with  diabetes  or prediabetes  report  more  pain  or have  increased  use  of  pain
medication  compared  to normoglycaemic  individuals.
Methods: Using  cross-sectional  data,  we  studied  928  men  and 1075  women  from  the  Helsinki  Birth  Cohort
Study  in  2001–2004  at a mean  age  of 61.5 years.  Glucose  regulation  was  assessed  with  a 2-h  75  g  oral
glucose  tolerance  test,  and  applying  World  Health  Organization  criteria,  participants  were  defined  as
having  normoglycaemia,  prediabetes  (impaired  fasting  glucose  or impaired  glucose  tolerance),  newly
diagnosed  diabetes  or previously  diagnosed  diabetes.  Self-reported  pain  intensity  and  interference  during
the  previous  4  weeks  was  estimated  using  the  RAND  36-Item  Health  Survey  1.0.  Information  on  use of
pain  medication  during  the  past  12 months  was  obtained  from  the  Social  Insurance  Institution  of  Finland.
Results:  There  was  no  difference  in  pain  intensity  or interference  between  glucose  regulation  groups
for  neither  men  nor  women  after  adjusting  for  covariates  (age,  body  mass  index,  education  years,  Beck
Depression  Inventory  and  physical  activity).  In  addition,  use of pain  medication  was  similar  between
glucose  regulation  groups.
Conclusions:  Although  pain  is a common  symptom  in the general  population,  impairments  in  glucose
regulation  alone  does  not  seem  to  increase  pain  among  older  individuals.








In the general population, pain is a common problem and an
important reason for seeking medical attention [1]. The prevalence
of chronic pain in European countries at population level has been
estimated to be around 12–30% [2], but studies from individual
countries have reported an even higher prevalence of more than
Abbreviations: ATC, Anatomical Therapeutic Chemical; BDI, Beck Depression
Inventory; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; LTPA,
leisure-time physical activity; NSAID, nonsteroidal anti-inflammatory drug; OGTT,
oral glucose tolerance test; RAND-36, RAND 36-Item Health Survey 1.0.
∗ Corresponding author at: Department of General Practice and Primary Health
Care, University of Helsinki, PO Box 20, FI-00014, Finland.
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0% [3,4]. In Finland, chronic pain affects approximately 19–35% of
he population [2,5] and pain is the primary symptom in nearly one
hird of the visits to health care centres [6]. Chronic pain has been
hown to interfere with activities of daily living and is associated
ith poor self-rated health, as well as multimorbidity and prema-
ure mortality [7–9]. The economic consequences of pain are also
ubstantial, both due to direct health care costs as well as indirect
osts such as loss of work days and productivity [7,10]. As the preva-
ence of chronic pain has been shown to increase with older age,
reventing and managing pain is important in order to decrease
he risk of disability and loss of independence [3,11].Chronic pain is common also among people with diabetes,
s more than half report some type of chronic pain [12,13]. An
mportant reason for this is peripheral neuropathy, which is a fre-
uent complication of diabetes and has been reported to cause
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chronic pain in 13–26% of people with diabetes [14]. In addition
to neuropathy, several non-neuropathic conditions and comor-
bidities associated with pain are often present in people with
diabetes, including rheumatic diseases, osteoarthritis, fibromyal-
gia and depression [13,15–17]. In fact, we recently showed that
comorbidities and depression, which frequently accompanies dia-
betes, might be more important causes of pain than diabetes itself
[13].
Prediabetes, i.e. impaired fasting glucose (IFG) and impaired glu-
cose tolerance (IGT), progresses to diabetes with an annual rate of
5–10% and has been shown to be associated with morbidity and pre-
mature mortality [18]. The relationship between prediabetes and
pain, however, is not well known. A previous study showed that
regional as well as widespread chronic pain were not associated
with prediabetes after adjusting for covariates, such as depression
and obesity [19]. It has been hypothesised that hyperglycaemia
present already in prediabetes may  cause neuropathy and even
painful neuropathy before the clinical onset of diabetes, but these
findings have been inconsistent [14,20].
To further elaborate on this matter, we used objective mea-
sures of glucose regulation and assessed whether different stages
of impairment in glucose regulation were associated with an
increased prevalence of pain or use of pain medications compared
to normoglycaemic older people at a mean age of 61.5 years. We
hypothesised that pain intensity and interference would increase
with more severe disturbances in glucose regulation.
2. Material and methods
2.1. Study population
This cross-sectional study was part of the Helsinki Birth Cohort
Study and included data from a sub-cohort of 8760 individuals born
between 1934 and 1944 at the Helsinki University Central Hospital.
All cohort members attended child welfare clinics and were living
in Finland in 1971, when Finnish residents were assigned a unique
identification number [21]. In the year 2000, a sample of 2902 indi-
viduals were selected using random-number tables and invited to a
clinical examination. This study included the 2003 individuals that
participated in the clinical examination and were examined once
between 2001 and 2004. All participants signed a written informed
consent. This study complies with the guidelines of the Declaration
of Helsinki and the study protocol was approved by the Ethics Com-
mittee of Epidemiology and Public Health of the Hospital District of
Helsinki and Uusimaa, as well the National Public Health Institute.
2.2. Glucose regulation
At the clinical examination, fasting plasma glucose was mea-
sured in all participants. Those with a self-reported history of
diabetes, a diabetes diagnosis in medical records, and those using
medications for diabetes were defined as having previously known
diabetes. All subjects underwent a standard 2-h 75 g oral glucose
tolerance test (OGTT), except those with previously known dia-
betes. The World Health Organization criteria from 1999 were used
to diagnose disturbances in glucose regulation [22]. IFG was defined
as a fasting plasma glucose level of 6.1–6.9 mmol/l, IGT as a 2-h
glucose level of 7.8–11.0 mmol/l, and diabetes as a fasting plasma
glucose level of at least 7.0 mmol/l or a 2-h glucose level of over
11.0 mmol/l. Those with no prior diagnosis of diabetes meeting the
criteria for diabetes at the clinical examination were defined as hav-
ing newly diagnosed diabetes. Prediabetes was defined as having
either IFG or IGT or both.
3
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.3. Pain and pain medication
Self-reported pain was  assessed at the clinical examination
sing the pain scale from the RAND 36-Item Health Survey 1.0
RAND-36) [23]. The two questions included were “How much bod-
ly pain have you had during the past 4 weeks?”, assessing pain
ntensity and was  scored on a six-level scale from “None” to “Very
evere”, and “During the past 4 weeks, how much did pain inter-
ere with your normal work (including both work outside the home
nd housework)?”, assessing pain interference and was  scored on
 five-level scale from “Not at all” to “Extremely”. The original
esponse for each question was  then recoded proportionally to a
iscrete scale ranging from 0 to 100, according to scoring instruc-
ions for RAND-36 [23]. A higher score indicated less pain intensity
nd interference.
Information on purchases of pain medication was obtained from
he Social Insurance Institution of Finland. Anatomical Therapeu-
ic Chemical (ATC) codes were used to search the register for
ain medications. Records of prescribed drugs over the previous
2 month-period prior to the clinical examination were included.
ain medications were coded into three groups: 1. Nonsteroidal
nti-inflammatory drugs (NSAID) and paracetamol; 2. Opioids,
ncluding weak, intermediate and strong opioids; 3. Neuropathic
rugs, including gabapentinoids and tricyclic antidepressants.
.4. Covariates and study variables
All participants were measured for height and weight, and body
ass index (BMI) was  calculated as kg/m2. Current health sta-
us was evaluated by self-reported diagnosis of chronic diseases,
ncluding hypertension, cardiovascular disease, cancer, rheumatic
isease, and depression. Questionnaires were used to collect
nformation on occupational status, educational attainment, and
ifestyle characteristics. The Beck Depression Inventory (BDI) was
sed to assess depressive symptoms at the time of examina-
ion. Physical activity was estimated using the validated Kuopio
schaemic Heart Diseases Risk Factor Study 12-month leisure-time
hysical activity (LTPA) questionnaire [24]. The results are pre-
ented as number of days per week performing any LTPA, including
oth non-conditioning (e.g. walking, gardening, yard work) and
onditioning (e.g. jogging, skiing, weightlifting). Self-rated health
as assessed with the question “How would you rate your health
uring the past 4 weeks?” and was  scored on a visual analog scale
anging from 0 to 100. A higher score indicated better self-rated
ealth.
.5. Statistical analysis
Data are presented as means with standard deviation (SD) and
s counts with percentages. Statistical comparison between glu-
ose regulation groups were done using Pearson’s chi-square or
isher–Freeman–Halton test for categorical variables and analy-
is of variance for continuous variables. In the case of violation
f the assumptions (e.g. non-normality) in continuous variables,
 bootstrap-type test and confidence intervals were used. The nor-
ality of variables was  evaluated using the Shapiro–Wilk W test.
or the analysis of pain intensity and pain interference between glu-
ose regulation groups, we adjusted for age, BMI, education years,
DI and LTPA. All analyses were performed using Stata version 15.1
StataCorp., College Station, Texas, USA).. Results
The study population included 928 men  and 1075 women
Table 1). The mean age for all participants was 61.5 (SD 2.9). A
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Table  1
Characteristics of cohort members grouped by glucose regulation.
Men  (n = 928) Women  (n = 1075)
NG Prediabetes New DM Known DM p NG Prediabetes New DM Known DM p
N 441 305 90 92 608 332 75 60
Age  (years), mean (SD) 61.3 (2.8) 61.9 (2.9) 61.5 (2.8) 61.1 (2.6) 0.013 61.3 (2.9) 61.8 (3.3) 62.3 (3.0) 61.2 (2.8) 0.007
Occupational status, n (%) 0.29 0.12
Working 245 (56) 157 (51) 51 (57) 38 (41) 340 (56) 161 (48) 35 (47) 24 (40)
Unemployed 38 (9) 31 (10) 9 (10) 12 (13) 64 (11) 37 (11) 8 (11) 8 (13)
Retired 158 (36) 117 (38) 30 (33) 42 (46) 204 (34) 134 (40) 32 (43) 27 (47)
Education years, mean (SD) 12.6 (3.9) 12.5 (3.6) 12.0 (3.5) 11.8 (3.6) 0.16 12.2 (3.6) 12.0 (3.4) 11.2 (3.2) 11.5 (3.2) 0.072
BMI  (kg/m2), mean (SD) 26.4 (3.4) 27.7 (3.7) 29.7 (6.0) 30.7 (4.7) <0.001 26.5 (4.6) 28.6 (4.8) 29.7 (5.5) 32.4 (6.0) <0.001
Current smoker, n (%) 133 (30) 84 (28) 27 (30) 26 (28) 0.88 124 (20) 64 819) 16 (21) 17 (28) 0.46
Alcohol consumption, n (%) 0.090 0.048
None  37 (8) 19 (6) 6 (7) 9 (8) 42 (7) 19 (6) 10 (13) 7 (12)
Less  than once per week 118 (27) 74 (24) 28 (31) 38 (41) 318 (52) 171 (52) 44 (59) 37 (62)
1–2  times per week 183 (42) 139 (46) 34 (38) 31 (34) 183 (30) 93 (28) 16 (21) 12 (20)
3  times or more per week 101 (23) 73 (24) 21 (24) 14 (15) 63 (10) 47 (14) 5 (7) 4 (7)
LTPA  days/week, mean (SD) 2.8 (1.8) 2.6 (2.0) 2.5 (1.9) 2.3 (1.7) 0.072 2.6 (1.9) 2.3 (1.9) 2.4 (1.9) 2.8 (1.8) 0.046
Health status, n (%)
Hypertension 103 (23) 97 (32) 46 (51) 64 (70) <0.001 133 (22) 129 (39) 36 (48) 36 (60) <0.001
Cardiovascular disease 32 (7) 31 (10) 12 (13) 26 (28) <0.001 17 (3) 27 (8) 4 (5) 7 (12) <0.001
Cancer 23 (5) 16 (5) 8 (9) 2 (2) 0.25 54 (9) 28 (8) 7 (9) 3 (5) 0.77
Rheumatic disease 11 (2) 7 (2) 2 (2) 0 (0) 0.57 18 (3) 5 (2) 5 (7) 1 (2) 0.082
Depression 45 (10) 28 (9) 5 (6) 13 (14) 0.26 81 (13) 45 (14) 12 (16) 16 (27) 0.041
Self-rated health (VAS), mean (SD) 78 (18) 76 (19) 77 (17) 73 (21) 0.15 75 (19) 74 (20) 76 (21) 71 (23) 0.26
































increased prevalence of pain in previous studies. Mäntyselkä et al.NG = normoglycaemia; New DM = diabetes diagnosed at oral glucose tolerance tes
index;  LTPA = leisure-time physical activity; VAS = visual analog scale; BDI = Beck D
total of 92 (9.9%) men  and 60 (5.6%) women had a previous his-
tory of diabetes. Based on the OGTT, prediabetes was diagnosed in
305 (32.9%) men  and 332 (30.9%) women, whereas diabetes was
diagnosed in 90 (9.7%) men  and 75 (7.0%) women. For both men
and women there were differences between the glucose regulation
groups in relation to age, BMI  and prevalence of cardiovascular dis-
ease and hypertension. In addition, prevalence of depression and
alcohol consumption as well as LTPA differed between the glucose
regulation groups, but only in women. Among men  on the other
hand, there was a significant difference in mean BDI score between
the glucose regulation groups. There was no difference in self-rated
health between the groups of glucose regulation for neither men
nor women.
During the previous 4 weeks, pain of at least moderate inten-
sity was reported by 15.0% of men  and 21.6% of women. The mean
intensity score was 78.2 (SD 24.1) among men  and 73.4 (SD 24.9)
among women, equivalent to an intensity of “very mild” to “mild”.
The mean score for pain intensity in each glucose regulation group
is shown in Fig. 1. There was no difference in pain intensity across
the glucose regulation groups (p = 0.56 for men  and p = 0.96 for
women) after adjusting for covariates.
Further, 10.0% of men  and 14.1% of women reported that pain
had interfered at least at a moderate level with their ability to work
during the previous 4 weeks. Men  and women reported a mean
interference score of 87.7 (SD 21.1) and 84.0 (SD 21.7), respec-
tively, corresponding to an interference of “not at all” to “a little
bit”. Fig. 2 illustrates the amount of pain interference in each glu-
cose regulation group, with no significant difference between the
groups (p = 0.16 for men  and p = 0.57 for women) after adjusting for
covariates.
Table 2 shows the use of pain medication across the glu-
cose regulation groups. Among men, 22.2% had been prescribed
pain medication during the previous 12 months, whereas the
corresponding number was 30.8% among women. There was no
significant difference in the use of pain medications between the
different glucose regulation groups for neither men  (p = 0.76), nor
women (p = 0.64). The most commonly prescribed pain medications
for both men  and women were NSAID or paracetamol. Neuropathic
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sion Inventory.
iagnosed diabetes group and by none of those with previously
nown diabetes.
. Discussion
In this cross-sectional study of older people, we found that
oderate pain or pain with higher intensity occurred in one fifth
f women  and in nearly one sixth of men. However, pain did
ot markedly interfere with the participants’ ability to perform
heir work. We  found no increase in pain intensity or interference
mong people with prediabetes or diabetes compared to people
ith normoglycaemia. The use of pain medication was similar
cross the glucose regulation groups, with no increase in prescribed
edications for neuropathic pain among those with diabetes or
rediabetes. In addition, there was  no difference in self-rated health
etween the different groups of glucose regulation. We  found
o indication supporting our hypothesis that more severe distur-
ances in glucose regulation would be associated with increased
ain.
The prevalence of impaired glucose regulation in our study
as  similar to previous studies in the Finnish population. Saaristo
t al. [25] reported that among men  aged 55–64 years the preva-
ence of diabetes and prediabetes were approximately 17% and
7%, respectively. The corresponding numbers for women in the
ame age group were approximately 12% for diabetes and 20% for
rediabetes. Compared to other European countries, the preva-
ence of diabetes and impaired glucose tolerance in Finland do
ot differ notably [26]. We  found that approximately half of those
ith diabetes were previously undiagnosed, which in accordance
ith previous studies suggests that diabetes is underdiagnosed in
inland [25]. The prevalence of pain in our study was also similar to
hat has been reported in other European countries, with a mean
revalence of 19% for moderate to severe pain [2].
Contrary to our findings, diabetes has been associated with an19] reported that diabetes was  associated with a three-fold odds
f chronic pain at multiple sites, but not with an increased odds
f chronic regional pain. In a sample of 100 individuals with dia-
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Fig. 1. Pain intensity for men and women  across glucose regulation groups. Values were adjusted for age, body mass index, education years, Beck Depression Inventory and
leisure-time physical activity. Whiskers indicate 95% confidence intervals. NG = normoglycaemia, New DM = diabetes diagnosed at oral glucose tolerance test, Known DM =
diabetes  diagnosed before oral glucose tolerance test.
Fig. 2. Pain interference for men  and women across glucose regulation groups. Values were adjusted for age, body mass index, education years, Beck Depression Inventory
and  leisure-time physical activity. Whiskers indicate 95% confidence intervals. NG = normoglycaemia, New DM = diabetes diagnosed at oral glucose tolerance test, Known
DM  = diabetes diagnosed before oral glucose tolerance test.
Table 2
Use of pain medication presented as frequencies and proportions.
Men  (n = 928) Women  (n = 1075)
NG Prediabetes New DM Known DM p NG Prediabetes New DM Known DM p
(n  = 441) (n = 305) (n = 90) (n = 92) (n = 608) (n = 332) (n = 75) (n = 60)
Any pain medication 95 (22) 72 (24) 17 (19) 22 (24) 0.76 188 (31) 96 (29) 27 (36) 20 (33) 0.64
NSAID or paracetamol 90 (20) 68 (22) 17 (19) 18 (20) 0.86 184 (30) 91 (27) 26 (35) 18 (30) 0.61
Opioids 11 (2) 6 (2) 1 (1) 6 (7) 0.12 7 (1) 7 (2) 1 (1) 3 (5) 0.12
Neuropathic pain medication 4 (1) 2 (1) 1 (1) 0 (0) 0.88 7 (1) 3 (1) 1 (1) 0 (0) 0.89
Gabapentinoids 3 (1) 1 (1) 0 (0) 0 (0) 1 (0) 0 (0) 0 (0) 0 (0)





















NG = normoglycaemia; New DM = diabetes diagnosed at oral glucose tolerance test; 
anti-inflammatory drug.
betes and 50 controls there was a significantly greater prevalence
of fibromyalgia in those with diabetes, and fibromyalgia was also
associated with a higher HbA1c among those with diabetes [16].
Diabetes has also been associated with osteoarthritis and in a meta-
analysis comprised of 49 studies, those with diabetes had a nearly
50% greater risk of having osteoarthritis compared to those with-
out diabetes [27]. On the contrary, we have previously shown in a
study including over 1000 individuals, that diabetes was  not asso-
ciated with pain after controlling for covariates [13]. Among those
with diabetes, pain was more strongly associated with depressive
symptoms and the number of comorbidities than with diabetes
itself.
Although diabetic neuropathy has been found to be an impor-
tant risk factor for chronic pain [28], we did not find an increase in
the use of neuropathic pain medications among individuals with
diabetes in our study. Duration of diabetes has been shown to
increase the risk of neuropathy [14], but we found no difference
in use of neuropathic pain medication or pain intensity between
those with newly diagnosed diabetes and previously known dia-
betes. Thus, our findings suggest that neuropathy does not increase
the burden of chronic pain for those with diabetes compared to
those without diabetes. Some previous studies have also suggested
that neuropathic pain may  develop already at a stage of prediabetes,
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opathy have an increased prevalence of prediabetes, in particularly
GT [29]. On the other hand, Dyck et al. assessed the association
etween objectively measured glucose regulation and neuropa-
hy and found no increased prevalence of neuropathy for those
ith prediabetes compared to those with normoglycaemia [20].
lthough we  did not evaluate neuropathy in our study, we found no
vidence suggesting increased amount of neuropathic pain among
hose with prediabetes compared to individuals with normogly-
aemia, as both use of pain medication and pain intensity and
nterference were similar in both groups.
The absence of an association between impaired glucose regu-
ation and pain in our study may  be due to several reasons. First,
e included any duration of pain that had occurred during the pre-
ious month, whereas many previous studies have included only
hronic pain. This naturally excludes individuals with sub-chronic
ain which could potentially occur often also among those with
ormoglycaemia and less severe impairments in glucose regula-
ion. Second, studies relying solely on self-reported diagnosis of
iabetes are unable to account for those with undiagnosed dia-
etes. These individuals may  have less pain than those with a longer
uration of diabetes, and this may  cause bias in the association
etween diabetes and pain. Third, differences in sample age groups
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Our results should encourage physicians to actively follow-up
on glycaemic control and treatment of individuals with prediabetes
and diabetes. Although diabetes is associated with several comor-
bidities, advances in the management of hyperglycaemia and other
risk factors, as well as improved patient education may  be a reason
for improved overall health status for those with diabetes [32,33].
Effective primary prevention of neuropathy in diabetes and subse-
quently prevention of neuropathic pain could be one explanation
why the use of neuropathic pain medication was  low in our study
population. The mean age of our sample was 61.5 years, and chronic
pain may  develop slowly over several years for individuals with
impaired glucose regulation. Thus, by managing risk factors and
comorbidities associated with diabetes and prediabetes it could
be possible to slow down the development of chronic pain and
minimise its intensity and progression [34,35].
This study has several strengths. We  included over 2000 indi-
viduals, both men  and women, from a well-characterised birth
cohort. Glucose regulation was assessed objectively using OGTT,
thereby diagnosing impairments in glucose regulation with high
precision. Previous studies have shown that half of those with
previously undiagnosed diabetes are diagnosed only by the OGTT
and remain undiagnosed when assessing glucose regulation sim-
ply with fasting plasma glucose or HbA1c [36]. Pain was  assessed
with the RAND-36, which is similar to the SF-36 Health Survey and
one of the most widely used instruments to assess health related
quality of life [37]. The survey is self-administered, easy to use and
takes under 10 min  to complete. It is a generic measure of health
status and thereby not specific for age or disease. The surveys have
also been validated and shown to be reliable in the Finnish general
population [38].
The cross-sectional design of this study can be considered a
weakness. We  were unable to evaluate the long-term associations
between impaired glucose regulation and the intensity and inter-
ference of pain. Therefore, we cannot exclude that impairments in
glucose regulation increase the risk of pain as the individuals age.
We acquired information on several different covariates, however,
we were not able to assess the prevalence of complications associ-
ated with diabetes, including neuropathy. As ATC codes were used
to access information on prescribed drugs, we were not able to
exclude pain medications used for other indications than pain. We
also acknowledge the possibility of a participation bias of healthier,
community-dwelling participants in our study. The study popula-
tion is a homogenous group of Caucasians of similar age from a
restricted area in Finland, which should be taken into consideration
when interpreting the results.
In conclusion, although pain is common among older people,
disturbances in glucose regulation does not seem to increase the
risk of pain compared to those with normoglycaemia. However,
future longitudinal studies are needed to assess the long-term asso-
ciation between impaired glucose regulation and pain.
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